Netilmicin in the treatment of severe or complicated urinary tract infections

Area of Science:

• Pharmacology
• Infectious Diseases
• Nephrology

Background:

• Netilmicin is a new aminoglycoside antibiotic.
• It shares pharmacological properties with established antibiotics like gentamicin, tobramycin, and sisomicin.

Purpose of the Study:

• To evaluate the efficacy and safety of netilmicin in treating severe or complicated urinary tract infections (UTIs).
• To compare the ototoxicity and nephrotoxicity profiles of netilmicin with other clinically available aminoglycosides based on animal studies.

Main Methods:

• A seven-day course of netilmicin was administered to 15 patients with severe or complicated UTIs.
• Patient outcomes, including infection eradication, side effects, ototoxicity, and renal function (plasma creatinine levels), were monitored.

Main Results:

• Fourteen out of 15 patients (93%) with severe or complicated UTIs were cured with netilmicin treatment.
• No significant side effects or ototoxicity were detected in the patient group.
• Four patients experienced reversible renal function deterioration (plasma creatinine increase ≥ 0.03 mmol/l).
• Experimental animal studies indicated netilmicin is less ototoxic and nephrotoxic than other aminoglycosides.

Conclusions:

• Netilmicin is a highly effective antibiotic for treating severe and complicated urinary tract infections.
• The drug exhibits a favorable safety profile with minimal ototoxicity and nephrotoxicity, potentially superior to existing aminoglycosides.
• Further large-scale comparative trials in humans are warranted to confirm netilmicin's reduced toxicity and its role in treating gram-negative sepsis.